SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST and participate in one-on-one investor meetings.
The webcast of the presentation will be accessible here and in the investor section of 89bio’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Sheryl Seapy
Real Chemistry
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$10.91 |
Daily Change: | 0.13 1.21 |
Daily Volume: | 370,720 |
Market Cap: | US$1.590B |
February 27, 2025 February 03, 2025 January 27, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load